James D Griffin Selected Research

midostaurin

11/2019	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
1/2018	Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
8/2017	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
12/2008	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
7/2007	Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
12/2005	FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
7/2005	Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
1/2005	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
10/2004	PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
2/2003	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James D Griffin Research Topics

Disease

32	Neoplasms (Cancer) 11/2023 - 11/2002
28	Leukemia 01/2022 - 06/2002
25	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2017 - 01/2002
23	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023 - 01/2003
8	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2015 - 10/2003
7	Hematologic Neoplasms (Hematological Malignancy) 11/2023 - 06/2004
6	Philadelphia Chromosome 12/2014 - 10/2003
5	Myeloid Leukemia (Leukemia, Myelocytic) 12/2017 - 11/2002
5	Hypereosinophilic Syndrome (Loeffler Endocarditis) 05/2010 - 03/2003
4	COVID-19 06/2023 - 08/2020
4	Systemic Mastocytosis 11/2019 - 07/2005
4	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2010 - 10/2003
3	Infections 01/2023 - 08/2020
3	Blast Crisis (Blast Phase) 05/2007 - 04/2003
3	Multiple Myeloma 12/2005 - 09/2002
2	Malignant Mesothelioma 01/2021 - 12/2020
2	Genetic Translocation (Chromosomal Translocation) 10/2015 - 12/2005
2	Disease Progression 08/2009 - 07/2007
2	Lymphoma (Lymphomas) 12/2005 - 10/2004
2	Essential Thrombocythemia 11/2005 - 04/2005
2	Polycythemia Vera 11/2005 - 04/2005
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 11/2005 - 10/2004
2	Primary Myelofibrosis (Myelosclerosis) 11/2005 - 04/2005
2	Carcinogenesis 10/2005 - 10/2003
2	Hematologic Diseases (Blood Diseases) 01/2005 - 05/2002
1	Reinfection 06/2023
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Immune System Diseases (Immune Disorders) 01/2017

Drug/Important Bio-Agent (IBA)

29	Phosphotransferases (Kinase)IBA 01/2023 - 01/2002
19	Imatinib Mesylate (Gleevec)FDA Link 12/2014 - 01/2002
17	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2017 - 05/2002
14	Tyrosine Kinase InhibitorsIBA 12/2017 - 06/2002
11	midostaurinIBA 11/2019 - 06/2002
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 06/2004
9	nilotinib FDA Link 12/2017 - 07/2005
8	Tyrosine (L-Tyrosine)FDA Link 05/2010 - 01/2003
7	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2010 - 02/2003
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 01/2003
4	Dasatinib (BMS 354825)FDA Link 12/2014 - 12/2010
3	Antiviral Agents (Antivirals)IBA 06/2023 - 08/2020
3	VaccinesIBA 06/2023 - 08/2020
3	EnzymesIBA 01/2022 - 01/2005
3	CytokinesIBA 01/2017 - 11/2002
3	TOR Serine-Threonine KinasesIBA 01/2015 - 11/2002
3	Platelet-Derived Growth Factor alpha ReceptorIBA 05/2010 - 03/2003
3	Growth Factor ReceptorsIBA 08/2009 - 04/2004
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2005 - 09/2002
2	Protein Kinases (Protein Kinase)IBA 01/2023 - 12/2008
2	gilteritinibIBA 01/2023 - 11/2019
2	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2017
2	Janus Kinase 2IBA 01/2022 - 11/2005
2	Glucose (Dextrose)FDA LinkGeneric 07/2015 - 10/2010
2	Drug CombinationsIBA 11/2014 - 07/2007
2	STAT5 Transcription FactorIBA 07/2012 - 03/2011
2	Pimozide (Orap)FDA Link 07/2012 - 03/2011
2	Adenosine Triphosphate (ATP)IBA 05/2010 - 07/2005
2	NF-kappa B (NF-kB)IBA 05/2010 - 04/2010
2	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 12/2006 - 10/2003
2	Sirolimus (Rapamycin)FDA Link 06/2005 - 03/2004
2	bcr-abl Fusion ProteinsIBA 02/2005 - 10/2003
1	Chimeric Antigen ReceptorsIBA 11/2023
1	AntibodiesIBA 06/2023
1	nintedanibIBA 01/2023
1	1-dodecylpyridoxal (PLD)IBA 01/2023
1	Histone MethyltransferasesIBA 01/2022
1	tazemetostatIBA 01/2022
1	Deubiquitinating EnzymesIBA 01/2022
1	Histone DemethylasesIBA 01/2021
1	ChromatinIBA 01/2021
1	Atovaquone (Mepron)FDA Link 12/2020
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	Ligases (Synthetase)IBA 01/2020
1	UbiquitinIBA 01/2020
1	avapritinibIBA 11/2019
1	Sorafenib (BAY 43-9006)FDA Link 11/2019
1	crenolanibIBA 11/2019
1	quizartinibIBA 11/2019
1	tyrosine receptor (receptor, tyrosine)IBA 11/2019
1	NOX-A12IBA 12/2017
1	Nucleotide AptamersIBA 12/2017
1	OligonucleotidesIBA 12/2017
1	NADP (NADPH)IBA 09/2017
1	Phosphogluconate Dehydrogenase (Dehydrogenase, Phosphogluconate)IBA 09/2017
1	Syk KinaseIBA 08/2017
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 11/2016
1	idelalisibIBA 08/2016
1	NVP-CGM097IBA 10/2015
1	1,4-alpha-Glucan Branching Enzyme (Glycogen Branching Enzyme)IBA 07/2015
1	Adenylate KinaseIBA 07/2015
1	GlycogenIBA 07/2015
1	Uridine Diphosphate (UDP)IBA 07/2015
1	Glycogen Synthase (Synthase I)IBA 07/2015

Therapy/Procedure

25	Therapeutics 11/2023 - 04/2003
2	Drug Therapy (Chemotherapy) 11/2023 - 01/2005
2	Hematopoietic Stem Cell Transplantation 01/2023 - 11/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2023
1	Precision Medicine 10/2021